Stimulant Found in Diet Drug; Possible Risk for Cardiovascular Injury

RegeneSlim appetite control dietary supplement has been subject to a nationwide recall because FDA analysis confirmed the presence of DMAA. DMAA is also known as 1,3-dimethylamylamine, methylhexanamine, or geranium extract. DMAA is commonly used as a stimulant, pre-workout, and weight loss ingredient in dietary supplement products. The FDA has warned that DMAA is potentially dangerous to health as it can narrow blood vessels and arteries, which can cause a rise in blood pressure or other cardiovascular problems such as shortness of breath, arrhythmias, tightening in the chest, and heart attack.


RegeneSlim is sold and distributed through a direct sales force within the United States and Puerto Rico, and through online sales, for both personal consumption and retail sales. The affected lot numbers include lot # EX0616R15814 and lot #11414RE5516.


This recall was the result of FDA analysis confirming the presence of DMAA in RegeneSlim and the manufacturer’s sampling. The manufacturer, Regeneca Worldwide, a division of VivaCeuticals, Inc., Las Vegas, NV, continues to investigate what caused the problem.


See the Recall


See also Medical Law Perspectives, May 2013 Report: Drugs, Dosage, and Damage: Physician Liability for Prescribing or Administering Medication


See also Medical Law Perspectives, November 2013 Report: Diagnosis and Treatment of Heart Attacks: Liability Issues